ArticleScientific reports2026
Hematological parameters as predictive indicators of disease stage in patients with cervical cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHematological abnormalities are highly common in cervical cancer and may serve as key indicators of disease progression. This study evaluates the predictive value of routine hematological parameters in identifying the stage of cervical cancer. This comparative cross-sectional study enrolled 200 women with cervical cancer, categorized into early and advanced clinical stages groups (100 per group). A consecutive sampling technique was employed to select the study participants. Three milliliters of venous blood were collected from each participant for hematological analysis. Data analysis was performed using Stata version 17 software. The Mann-Whitney U test was employed to compare hematological profiles between the two groups. Spearman's rank correlation was used to assess the relationship between hematological parameters and the stage of cervical cancer. Furthermore, ROC curve analysis was used to determine the predictive values and optimal cut-off points of hematological parameters in identifying disease stage. A p value < 0.05 was considered statistically significant. Hematological parameters, including hemoglobin (Hb) levels, hematocrit, and red blood cell (RBC) indices, were significantly lower in patients with advanced-stage cervical cancer compared to those in the early stage (p < 0.05). Conversely, white blood cell (WBC) count, platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) were significantly higher in the advanced-stage group. ROC curve analysis revealed that NLR had the highest discriminative power (AUC = 0.9049), followed by neutrophil count (AUC = 0.8500), WBC count (AUC = 0.8248), PLR (AUC = 0.7776), MLR (AUC = 0.7466), and platelet count (AUC = 0.7335). Disease progression in cervical cancer is associated with a significant decline in RBC parameters and a concurrent elevation in inflammatory markers. WBC, neutrophil, and platelet counts, as well as NLR, PLR, and MLR, demonstrated desirable predictive performance in discriminating advanced-stage from early-stage cervical cancer. These hematological parameters may serve as potential indicators of disease stage; however, further prospective, multicenter studies are required to confirm these findings and validate their clinical applicability.
Indexed as
Identifiers
41998030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.